ESIDRIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESIDRIX (ESIDRIX).
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine. |
| Excretion | Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%. |
| Half-life | Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment. |
| Protein binding | Approximately 75% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is 0.1-0.2 L/kg; indicates limited extravascular distribution consistent with hydrophilic properties. |
| Bioavailability | Oral: bioavailability is approximately 80-90%. |
| Onset of Action | Oral: diuresis begins within 1-2 hours; peak effect at 2-4 hours. |
| Duration of Action | Oral: diuretic effect lasts approximately 6-12 hours; antihypertensive effect persists for 24 hours with once-daily dosing. |
| Molecular Weight | 297.74 |
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
| Dosage form | TABLET |
| Renal impairment | GFR 25-50 mL/min: administer every 12 hours; GFR 10-25 mL/min: administer every 24 hours; GFR <10 mL/min: not recommended due to ineffectiveness. |
| Liver impairment | Child-Pugh Class B or C: reduce dose by 50% or use with caution due to risk of electrolyte disturbances and hepatic encephalopathy. |
| Pediatric use | 1-2 mg/kg orally once daily; maximum 50 mg/day. |
| Geriatric use | Start at 12.5-25 mg orally once daily; monitor electrolytes and renal function; adjust dose based on response and tolerability. |
| 1st trimester | Avoid. Crosses placenta; may cause fetal hyponatremia, electrolyte disturbances. Limited human data; animal studies suggest risk. |
| 2nd trimester | Avoid. Potential for fetal/neonatal jaundice, thrombocytopenia, electrolyte imbalance. Use only if clearly needed. |
| 3rd trimester | Avoid. May cause neonatal thrombocytopenia, electrolyte disturbances, and prolong labor due to uterine relaxation. |
Clinical note
Comprehensive clinical and safety monograph for ESIDRIX (ESIDRIX).
| Placental transfer | Crosses placenta; achieves fetal serum concentrations approximately 15% of maternal levels. |
| Breastfeeding | Excreted into breast milk; small amounts. Monitor infant for electrolyte disturbances, particularly hyponatremia and hypokalemia. Use caution, especially in premature or ill infants. |
■ FDA Black Box Warning
Not applicable
| Serious Effects |
AnuriaHypersensitivity to hydrochlorothiazide or sulfonamide derivativesHepatic coma or pre-comaSevere renal impairment (e.g., anuria)
| Precautions | Hypokalemia, Hyperuricemia, Hypomagnesemia, Hypercalcemia, Orthostatic hypotension, Photosensitivity, Systemic lupus erythematosus exacerbation, Sulfonamide allergy cross-sensitivity |
| Food/Dietary | Avoid high-sodium foods as they reduce antihypertensive efficacy. Limit potassium-rich foods (bananas, oranges) only if directed; hypokalemia risk is counteracted by high intake. Grapefruit juice may decrease HCTZ absorption; separate intake by 4 hours. Reduce alcohol intake to prevent additive hypotension. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; potential for fetal bradycardia and hypotension. Second and third trimesters: Increased risk of fetal hypotension, renal dysfunction, oligohydramnios, and skull ossification delays. |
| Fetal Monitoring | Monitor maternal blood pressure, electrolytes, and renal function. Fetal ultrasound for growth and amniotic fluid volume; consider fetal heart rate monitoring. |
| Fertility Effects | No established adverse effects on human fertility; animal studies show no significant impairment. |
| Clinical Pearls |
| Hydrochlorothiazide (HCTZ) in Esidrix may unmask diabetes (hyperglycemia), exacerbate gout (hyperuricemia), and cause hypokalemia (especially at high doses). Monitor electrolytes and renal function. Sunset yellow dye in tablets may cause allergic reactions in aspirin-sensitive patients. |
| Patient Advice | Take in the morning to avoid nocturia. · Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur. · Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat. · May increase blood sugar; monitor if diabetic. · Do not take with alcohol or other blood pressure medications without consulting doctor. |